Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Roche Holding Ltd.    RHO5   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ROCHE HOLDING LTD.
09/22 ROCHE : receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of ..
09/22 ROCHE : unloads another plant in deal with Recipharm that saves 200 jobs
09/22 ROCHE : receives EU approval of Gazyvaro for people with previously untreated ad..
09/22 ROCHE : receives European approval for Actemra /RoActemra in giant cell arteriti..
09/21 HALOZYME THERAPEUTICS : Licenses New Enhanze Target For $30 Million Upfront Paym..
09/21 ROCHE : Best way to counter Diabetes is Healthy Diet, Exercise and constant moni..
09/21 ROCHE : Spanish plant becomes eighth solid dose site for Recipharm
09/21 ROCHE : Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference C..
09/20 ABBVIE : and Roche plan Venclexta combo filings in leukaemia
09/20 ROCHE : FDA locks down combo immunotherapy trials, Roche added to hold
09/20 RECIPHARM PUBL : signs long-term manufacturing agreement with major new customer..
09/20 ROCHE : $61,880 Federal Contract Awarded to Roche Diagnostics
09/19 ROCHE : Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan hel..
09/18 ROCHE : Phase III Data Showed That Venclexta Plus Rituxan Helped People With Pre..
09/18 ROCHE : Partitions
09/15 Halozyme signs mammoth drug partnerships
09/14 FOUNDATION MEDICINE : New Breast Cancer Findings from Foundation Medicine Inc. R..
09/14 FOUNDATION MEDICINE : to Present Validation Data for Its Assay Measuring Tumor M..
09/14 ROCHE : 23andMe raises $250m in financing, research points towards its future
09/14 Roche faces prospect of second Rituxan biosimilar in US
09/14 ROCHE : Various medicinal products
09/14 FOUNDATION MEDICINE, INC. (NASDAQ : FMI) Files An 8-K Entry into a Material Defi..
09/13 ROCHE : Novartis scores but Roche misses in melanoma trials
09/13 ROCHE : under pressure as second rituximab biosimilar filed in US
09/13 ROCHE : La Roche College Recognized by U.S. News & World Report
09/13 ROCHE : Results of a six-month study combining Roche’s Esbriet with ninted..
09/12 ROCHE : Genentech Provides Update on First Lampalizumab Phase III Study for Geog..
09/11 ROCHE : Taselisib Added to Letrozole Boosts Response in Breast Cancer
09/11DJROCHE : Zelboraf Study Failed to Meet Endpoint
09/11 ROCHE : announces phase III study results of Zelboraf for adjuvant treatment of ..
09/09 ROCHE : Analysis services
09/09 LEAP THERAPEUTICS : Announces Collaboration With EORTC to Evaluate DKN-01 in Com..
09/09 ROCHE : Provides Update on First Lampalizumab Phase III Study for Geographic Atr..
09/09 ROCHE : South City High unveils $7.8 million Science Garage
09/09 ROCHE : hopes blood test will predict immunotherapy efficacy
09/09 AstraZeneca rebuilds cancer drug hopes with new lung data
09/08 GENENTECH : Provides Update on First Lampalizumab Phase III Study for Geographic..
09/08 MOLECULIN BIOTECH : to collaborate on combining its WP1122 Brain Cancer Drug Can..
09/08 ROCHE : UK is first to receive Roche`s rare lung cancer drug
09/08 ROCHE : announces progress in biomarker science in cancer immunotherapy at the E..
09/08 Merck's immunotherapy, chemo mix shows extended lung cancer gains
09/07 FOUNDATION MEDICINE : Robbins Geller Rudman & Dowd LLP Updates Investors Regardi..
09/07 FOUNDATION MEDICINE : to Present at the 2017 Wells Fargo Healthcare Conference
09/07 ROCHE : Interior Design Student at La Roche Earns Prestigious $30,000 Scholarshi..
09/07 ROCHE : ranked again the most sustainable healthcare company in the Dow Jones Su..
09/07 FOUNDATION MEDICINE : The Klein Law Firm Reminds Investors of a Class Action Com..
09/06 ROCHE : K&L Gates Boosts FDA Practice With Addition of Genentech Corporate Couns..
09/06 ROCHE : presents data from global phase III study showing significant clinical b..
09/04 ROCHE : Health and safety consultancy services
09/01 ROCHE : Special Notice - 66-- INTENT TO SOLE SOURCE Reagents and Consumables for..
08/31 CHUGAI PHARMACEUTICAL : Emicizumab Receives Priority Review Designation by FDA f..
08/31 ROCHE : FDA Approves Genentechs Actemra (Tocilizumab) for the Treatment of CAR T..
08/31 ROCHE : to present new data from its oncology portfolio at the 2017 European Soc..
08/31 ROCHE : FDA Approves Roche's Actemra/RoActemra (tocilizumab) for the Treatment o..
08/31 ROCHE : Open borders key to Swiss pharmas EU success
08/30 ROCHE : Federal Contracts Awarded by Federal Agencies in Illinois (Aug. 30)
08/30 ROCHE : Hardware consultancy services
08/30 ROCHE : FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treat..
08/30 ROCHE : FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment o..
08/30 ROCHE : cuts the price of cancer drug
08/29 ROCHE : HEALTHCARE - Roche cuts the price of cancer drug
08/29 ROCHE : $325.07 Million Federal Contract Awarded to Roche Diabetes Care
08/28 ROCHE : Sausage products
08/28 CHUGAI PHARMACEUTICAL : Approval of Actemrafor Additional Indications of Takayas..
08/28DJROCHE : Granted FDA Priority Review for Blood Cancer Treatment
08/28 ROCHE : FDA grants Priority Review for Roche’s Gazyva in previously untrea..
08/28 ROCHE : FDA Grants Priority Review for Genentech’s Gazyva in Previously Un..
08/26 ROCHE : This week's answers
08/26 ROCHE : COMPETITION - A bitter pill to swallow or a dose of their own medicine?
08/25 Orphan Diseases Market Key Players analysis – Bristol-Myers Squibb Comp..
08/25 ROCHE : FDA Grants Priority Review to Genentech`s Emicizumab for Hemophilia A wi..
08/24 FOUNDATION MEDICINE : Cancer Treatment Centers of America® and Foundation Medici..
08/24 ROCHE : Genentech - FDA Grants Priority Review to Genentech's Emicizumab for Hem..
08/24 ROCHE : La Roche College Named a College of Distinction
08/24DJROCHE : Granted Priority Review by FDA for Hemophilia Drug
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 361 M
EBIT 2017 18 314 M
Net income 2017 11 181 M
Debt 2017 8 848 M
Yield 2017 3,46%
P/E ratio 2017 18,52
P/E ratio 2018 16,86
EV / Sales 2017 4,17x
EV / Sales 2018 3,93x
Capitalization 214 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | RHO5 | CH0012032048 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 277  CHF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-0.92%220 358
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633